Investor Relations
Join us in revolutionizing genetic data ownership and building the future of personalized medicine.
Investment Opportunity
Enigma Genetics™ is seeking early-stage partners to advance Phase I development of its self-sovereign genetic identity infrastructure.
With our patent-pending technology stack and first-mover advantage, we're positioned to capture significant value in the $40B+ genomics market while addressing growing privacy concerns and regulatory pressures facing traditional DNA testing companies.
Funding Details
Seed Round Target
$2.5M
Valuation Cap
$10M SAFE
Use of Funds
IP filings, MVP build, CRISPR partnerships, compliance
Traction
Provisional patent filed, Cypherglyph™ prototype, domains secured
Market Opportunity
$40B+ Market
Global genomics market growing at 15% CAGR through 2030
100M+ Users
Direct-to-consumer DNA tests sold globally with limited privacy protections
Regulatory Tailwinds
Increasing privacy regulations driving demand for secure genetic data solutions
Patent Protection
Proprietary technology with pending patents in key jurisdictions
Our Technology Advantage
Enigma Genetics has developed a comprehensive technology stack that addresses every aspect of genetic data sovereignty:
- •Cypherglyph™ - Cryptographic genetic identity system creating verifiable digital identities from DNA
- •GeneVault™ - Military-grade encrypted genomic storage with granular access controls
- •SignaChain™ - Transparent consent-based data exchange protocol
- •Unifacator™ - Interoperable framework connecting healthcare systems and research institutions
- •OmniMind™ - AI-powered epigenetic analysis and personalized health insights
Use of Funds Breakdown
- •40% - Product Development & Engineering
- •30% - Go-to-Market & User Acquisition
- •20% - Strategic Partnerships & Business Development
- •10% - Legal, Compliance & Patent Protection
Request Investment Materials
For detailed financial projections, market analysis, and our complete investor deck, please request access to our investor brief.